Inventor · disambiguated record
Jeremy Martin Davis
Also filed as: DAVIS JEREMY M · DAVIS JEREMY MARTIN
19 granted patents·8 pending applications·1,212 citations·filing 1996–2013
96Inventor score
Files withCELLTECH R&D LTD8UCB PHARMA SA7CELLTECH THERAPEUTICS LTD5HUTCHINGS MARTIN CLIVE2BROOKINGS DANIEL C1
Top patents by PatentIndex Score
27 records- 0198US6579983B15-cyano-2-aminopyrimidine derivativesCELLTECH R&D LTD·Filed 2000·Granted Jun 17, 2003·228 cites·5 claims
- 0298US6235746B1Substituted 2-anilinopyrimidines useful as protein kinase inhibitorsCELLTECH THERAPEUTICS LTD·Filed 1999·Granted May 22, 2001·290 cites·12 claims
- 0398US5958935ASubstituted 2-anilinopyrimidines useful as protein kinase inhibitorsCELLTECH THERAPEUTICS LTD·Filed 1996·Granted Sep 28, 1999·361 cites·23 claims
- 0494US6600037B14,5-disubstituted-2-aminopyrimidinesCELLTECH R&D LTD·Filed 2000·Granted Jul 29, 2003·56 cites·2 claims
- 0592US6599908B1Fused polycyclic 2-aminopyrimidine derivativesCELLTECH R&D LTD·Filed 2000·Granted Jul 29, 2003·47 cites·11 claims
- 0688US8394822B2Thieno-pyridine derivatives as MEK inhibitorsHUTCHINGS MARTIN CLIVE·Filed 2012·Granted Mar 12, 2013·13 cites·20 claims
- 0786US6057329AFused polycyclic 2-aminopyrimidine derivativesCELLTECH THERAPEUTICS LTD·Filed 1997·Granted May 2, 2000·63 cites·15 claims
- 0884US5922741A5-aminopyrazoles useful as tyrosine kinase inhibitorsCELLTECH THERAPEUTICS LTD·Filed 1997·Granted Jul 13, 1999·60 cites·16 claims
- 0983US8283359B2Thieno-pyridine derivatives as MEK inhibitorsHUTCHINGS MARTIN CLIVE·Filed 2008·Granted Oct 9, 2012·6 cites·16 claims
- 1082US7521460B2Thienopyridone derivatives as kinase inhibitorsUCB PHARMA SA·Filed 2004·Granted Apr 21, 2009·17 cites·11 claims
- 1181US7592455B2Bicyclic heteroaromatic compounds as kinase inhibitorsUCB PHARMA SA·Filed 2003·Granted Sep 22, 2009·16 cites·6 claims
- 1276US7795256B2Thieno-pyridinone derivatives as kinase inhibitorsUCB PHARMA SA·Filed 2004·Granted Sep 14, 2010·14 cites·9 claims
- 1376US7763729B2Bicyclic heteroaromatic derivativesUCB PHARMA SA·Filed 2008·Granted Jul 27, 2010·2 cites·19 claims
- 1476US7423047B2Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitorsCELLTECH R&D LTD·Filed 2003·Granted Sep 9, 2008·8 cites·18 claims
- 1572US8604051B2Thieno-pyridine derivatives as MEK inhibitorsUCB PHARMA SA·Filed 2013·Granted Dec 10, 2013·1 cites·20 claims
- 1667US7176215B2Bicyclic oxopyridine and oxopyrimidine derivativesCELLTECH R&D LTD·Filed 2002·Granted Feb 13, 2007·3 cites·15 claims
- 1766US6133257AFused polycyclic 2-aminopyrimidine derivativesCELLTECH THERAPEUTICS LTD·Filed 1998·Granted Oct 17, 2000·23 cites·9 claims
- 1862US7323464B2Pyridine and pyrimidine derivativesCELLTECH R&D LTD·Filed 2002·Granted Jan 29, 2008·3 cites·14 claims
- 1959US7456286B2Bicyclic heteroaromatic compounds as kinase inhibitorsUCB PHARMA SA·Filed 2003·Granted Nov 25, 2008·1 cites·4 claims
- 2058US2004235876A14,5-Disubstituted-2-aminopyrimidinesCELLTECH R&D LTD·Filed 2004·Application pending·0 cites
- 2156US2005171134A14,5-Disubstituted-2-aminopyrimidinesCELLTECH R&D LTD·Filed 2005·Application pending·0 cites
- 2255US2004180914A15-Cyano-2-aminopyrimidine derivativesCELLTECH R & D LIMTIED·Filed 2004·Application pending·0 cites
- 2355US2003212269A14.5-disubstituted-2-aminopyrimidinesFiled 2003·Application pending·0 cites
- 2451US2002147339A15-cyano-2-aminopyrimidine derivativesFiled 2002·Application pending·0 cites
- 2548US2010179185A1Novel Aminothienopyridinone Derivatives Processes for Preparing Them and Pharmaceutical Compositions ThereofUCB PHARMA SA·Filed 2007·Application pending·0 cites
- 2646US2006247269A1Thienopyridone derivatives as kinase inhibitorsBROOKINGS DANIEL C·Filed 2004·Application pending·0 cites
- 2742US2004122223A1Non-natural nucleotides and dinucleotidesFiled 2002·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jeremy Martin Davis files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →